- Details
- In this discussion, Ashish Kamat moderates a debate between Sia Daneshmand and Trinity Bivalacqua comparing the benefits of enhanced cystoscopy with blue light cystoscopy in TURBT to the benefits of perioperative chemotherapy following TURBT. Dr. Daneshmand discusses the role of blue light cystoscopy (BLC ®) in TURBT that there is an improvement in detecting tumors and their respective margins dur...
|
- Details
- Ashish Kamat is joined by Hugh Mostafid for a discussion on trans urethral resection of bladder tumor (TURBT) improvement, and the imperfections that impede TURBT success. Dr. Mostafid discusses current methods to optimize TURBT and highlights ways to improve surgical outcomes. He shares that by reviewing the current technique and outcomes and employing better imaging and instrumentation, TURBT ca...
|
- Details
- Joining Ashish Kamat are Arjun Balar and Peter Black to consider the use of nadofaragene firadenovec versus pembrolizumab for a patient with BCG unresponsive carcinoma in situ in the bladder where the patient is ineligible for a cystectomy. Dr. Balar speaks to the side of systemic checkpoint blockade, discussing the early trials using systemic checkpoint blockade and highlighting results of the KE...
|
- Details
- Ashish Kamat is joined by Wassim Kassouf, an expert in the bladder cancer field on Bacillus Calmette-Guérin unresponsive disease. Together they discuss the different treatment options in these patients, how the shortage of BCG will affect patient samples in clinical studies, and how to counsel patients with BCG-unresponsive carcinoma in situ. Biographies: Wassim Kassouf, MD, CM, FRCSC, is a Profes...
|
- Details
- Trinity Bivalacqua joins Ashish Kamat to discuss the role of blue light cystoscopy in bladder cancer treatment, specifically regarding non-muscle invasive disease. Dr. Bivalacqua emphasizes how risk stratification allows for personalization of care and highlights a case study of a patient with high-risk non-muscle invasive bladder cancer. Dr. Bivalacqua also explains how blue light cystoscopy can...
|
- Details
- Michael O'Donnell shares his insight into managing the current BCG shortage crisis, highlighting ways to make the most out of the current supply and explains a few alternative intravesical agents that could be used in place of BCG for treating patients with bladder cancer. Dr. O'Donnell explains how risk can be assessed while prioritizing high-risk patients and shares advice as to how treatment pl...
|
- Details
- Joshua Meeks joins Alicia Morgans to discuss the current BCG shortage and its implications for treatment options in the bladder cancer community. Dr. Meeks highlights clinical data on the matter presented by other clinicians at the conference, as well as his own personal expertise on how he manages the patient selection and the risk stratification process for BCG resources in his own clinic. Biogr...
|
- Details
- Recorded Date: April 18, 2020 Many of the tests used to diagnose and detect bladder cancer involve invasive procedures. Non-invasive testing options are equally effective and can be applied in this COVID-19 environment where we want to limit patients needing to come into the clinics for tests. In this discussion Neal Shore, Sima Porten, and Tom Nifong discuss Cxbladder a non-invasive, urine-based...
|
- Details
- For this Journal Club, Christopher Wallis, MD, and Zach Klasseen, MD discuss a recently published meta-analysis on treatment options for patients with non-muscle invasive bladder cancer unresponsive or refractory to BCG therapy. They provide context for this review and discuss the clinical relevance of managing the risk of recurrence in NMIBC. Biographies: Zachary Klaassen, MD, MSc, Urologic Oncol...
|
- Details
- Recorded Date: April 2, 2020 The ongoing pandemic involving severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and its resulting coronavirus disease 2019 (COVID-19) has caused widespread infection worldwide. Andrew DiNardo (infectious disease physician) and Paul Hegarty (urologist) join Ashish Kamat to discuss The BADAS Study: BCG vaccination As Defense Against SarsCov2: A randomized con...
|
